Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 5 | 8 |
| 2018 | 23 | 7 | 30 |
| 2019 | 31 | 15 | 46 |
| 2020 | 23 | 3 | 26 |
| 2021 | 12 | 2 | 14 |
| 2022 | 8 | 1 | 9 |
| 2023 | 5 | 0 | 5 |
| 2024 | 2 | 8 | 10 |
| 2025 | 11 | 1 | 12 |
| 2026 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
-
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517460.
-
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond. Physiol Rev. 2026 07 01; 106(3):1681-1756.
-
A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II Non-Small-Cell Lung Cancer from the Randomized KEYNOTE-671 Study. Eur J Cardiothorac Surg. 2026 03 10; 68(3).
-
Advances in Immunotherapy for Breast Cancer. Oncology (Williston Park). 2026 Feb 10; 40(1):8-15.
-
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Adv Ther. 2026 01; 43(1):333-355.
-
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. Cancer Res. 2025 11 14; 85(22):4521-4540.
-
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer. 2025 Nov; 209:108799.
-
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 11 10; 43(32):3526-3535.
-
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood. 2025 Jul 24; 146(4):471-481.